Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Inten

Indication
Acute Myeloid Leukemias

Other upcoming events for SNDX

Patent ExpiryPatent/Exclusivity Expiry: VYXEOS
Patent ExpiryPatent/Exclusivity Expiry: REVUFORJ

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Inten — SNDX Phase 3 Readout | BioSniper